Loading…

The evaluation of the role of CCK in the opioid modulation of the motility of the gastrointestinal tract in sheep

The participation of central cholecystokinin‐8 (CCK‐8) receptors in the modulatory effect of D‐Ala2, N‐Me‐Phe4, Gly5‐ol enkephalin (DAGO), a selective μ–opioid receptor agonist, on the spike burst activity of the gastrointestinal tract (rumen, reticulum, antrum, duodenum, colon and caecum) in sheep...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary pharmacology and therapeutics 1999-04, Vol.22 (2), p.153-160
Main Authors: Kania, B F, Brikas, P, Buéno, L, Fioramonti, J, Zaremba-Rutkowska, M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The participation of central cholecystokinin‐8 (CCK‐8) receptors in the modulatory effect of D‐Ala2, N‐Me‐Phe4, Gly5‐ol enkephalin (DAGO), a selective μ–opioid receptor agonist, on the spike burst activity of the gastrointestinal tract (rumen, reticulum, antrum, duodenum, colon and caecum) in sheep was investigated. DAGO was infused intracerebroventricularly (i.c.v.) at doses of 0.1–1 μg/kg body weight (BW).  It was shown that DAGO significantly inhibited myoelectrical activity of the wall of the forestomachs, abomasum and colon but stimulated this activity in the duodenum (rate of myoelectrical migrant complex‐MMC). The effects of DAGO were prevented by CCK‐8 antagonists (L‐364.718 and L‐365.260) previously infused at doses of 5–20 μg/kg BW.  The results of this present study indicate that central receptors of CCK‐8 participated in the modulatory action of an opioid on myoelectrical activity of the gastrointestinal tract in sheep. Furthermore, this result suggests that CCK‐8 is released in response to μ‐receptor stimulation, because CCK‐8 antagonists (L 364.718 and L 365.260) prevented the modulatory action of DAGO on the gastrointestinal motility in sheep.
ISSN:0140-7783
1365-2885
DOI:10.1046/j.1365-2885.1999.00190.x